Horizon Eye Care ophthalmologist Randall N. Stein, MD is the first physician in Charlotte to implant Alcon’s CyPass® Micro-Stent. Approved by the FDA in the summer of 2016, the CyPass Micro-Stent is a micro-invasive glaucoma surgical (MIGS) device designed to treat cataract patients with mild-to-moderate primary open-angle glaucoma. It is implanted just below the surface of the eye to enhance aqueous outflow and reduce intraocular pressure.
Dr. Stein, one of our glaucoma specialists alongside Dr. Joseph H. Krug and Dr. Vandana R. Minnal, says, “Alcon’s CyPass Micro-Stent is a key option to help improve the lives of people living with glaucoma. Not only is this a less invasive procedure than traditional glaucoma surgery, but it also lowers dependence on topical glaucoma medications.”
According to Alcon’s website, “Glaucoma refers to a group of diseases in which there is progressive damage of the optic nerve. It is the leading cause of blindness worldwide, affecting more than 60 million people globally. Early diagnosis of glaucoma is critical to managing the disease, as glaucoma is often asymptomatic and therefore can go undetected until it is at an advanced stage. As the disease progresses, patients may experience loss of peripheral (side) vision, tunnel vision or eye spots. Glaucoma can eventually result in irreversible loss of vision and blindness. Many glaucoma treatments address elevated pressure in the eye (intraocular pressure, or IOP), a major risk factor for optic nerve damage, and the only known modifiable risk factor for glaucoma.”
About the CyPass Micro-Stent
Alcon states, “The CyPass Micro-Stent is a prescription medical device with a CE mark indication for use (a) in conjunction with cataract surgery for the reduction of IOP in adult patients with mild to moderate primary open-angle glaucoma, and (b) for use in conjunction with cataract surgery or as a standalone procedure for the reduction of IOP in adult patients with primary open-angle glaucoma in cases where previous medical treatments have failed. Use of the CyPass Micro-Stent is contraindicated in eyes with angle-closure glaucoma, in eyes with traumatic, malignant, uveitic, or neovascular glaucoma or discernible congenital anomalies of the anterior chamber angle, and in patients with known intolerance or hypersensitivity to topical anesthetics, miotics, mydriatics, or polyimide. The surgeon should monitor the patient postoperatively for proper maintenance of IOP. If IOP is not adequately maintained after implantation of a CyPass Micro-Stent, additional therapy may be needed for IOP control.”
To download the patient brochure, click here.
To determine if you are a candidate for this minimally invasive, outpatient procedure, ask your Horizon Eye Care physician or call 704.365.0555 to set up a consultation. Or, request an appointment here right now.